Starts 5/11/2020 | Content Expires 5/11/2023
This course includes:
- Video presentation by a leading expert
- Pre- and post-exams to measure your understanding
- CME and MOC claiming online
Ashish Chintakuntlawar, PhD, MBBS
Ashish Chintakuntlawar (Chinta-Kuntaa-Laawar), MBBS PhD, Assistant Professor, Division of Medical Oncology at the Mayo Clinic Rochester. Area of expertise- Head and Neck and Endocrine Oncology. Research interests - Early stage therapeutic trials in Endocrine Oncology and Head and neck cancers. Indebted to collegaues for collaboration, and to grateful to patients for opportunity to be part of their life.
LEARNING OBJECTIVES
Upon completion of this activity, learners will be able to identify:
- Determine first line kinase inhibitor therapy options for advanced thyroid cancer
- Review adverse event profile of kinase inhibitor therapy
- Identify factors important in determining initiation of MKI therapy
MAINTENANCE OF CERTIFICATION
Successful completion of this CME activity enables the participant to earn up to .75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Your participation information will be shared with the ACCME, which will in turn report your points to ABIM. Successful completion of a course examination is required to earn ABIM MOC points.
ACCREDITATION AND DESIGNATION STATEMENTS
The American College of Endocrinology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Endocrinology designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
